Dodecyl Creatine Ester Micro-emulsion for Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Creatine Transporter Deficiency (CTD) are ineffective as pure creatine cannot penetrate cerebral cells, and experimental creatine derivatives lack stability and are toxic.
Innovation Solution
A nanoengineered delivery system using dodecyl creatine ester (DCE) incorporated in lipid nanocapsules, combined with omega-3 fatty acids and non-ionic surfactants, to create a micro-emulsion for nasal administration, bypassing the Blood-Brain Barrier and preventing degradation by plasma esterases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pure creatine is administered, then it cannot penetrate cerebral cells, but this limits treatment effectiveness for CTD
Solution Approach 1:
The patent uses lipid nanocapsules as intermediary carriers to transport creatine across the blood-brain barrier. The nanocapsules with size 50-200 nm facilitate creatine penetration into cerebral cells that pure creatine cannot access, thereby resolving the penetration issue while maintaining treatment effectiveness
Solution Approach 2:
The patent modifies the physical parameters of creatine delivery by formulating it into nanocapsules with specific size ranges (50-200 nm). This parameter change enables the creatine to cross the blood-brain barrier through nanoparticle-mediated transport mechanisms, overcoming the size and solubility limitations of pure creatine
2Object-affected harmful factors
If experimental creatine derivatives are used, then they may improve penetration, but they lack stability and are toxic
Solution Approach 1:
The patent segments the creatine molecule by converting it into creatine fatty esters (such as creatine octyl ester, creatine decyl ester, creatine dodecyl ester). This segmentation modifies the molecular structure to improve blood-brain barrier penetration while maintaining sufficient stability and reducing toxicity compared to earlier experimental derivatives
Solution Approach 2:
The patent creates a composite delivery system combining creatine fatty esters with lipid nanocapsules. This composite approach integrates the penetration-enhancing properties of fatty esters with the protective and stabilizing characteristics of lipid nanocapsules, achieving both improved penetration and enhanced stability with reduced toxicity
3Object-affected harmful factors
If lipid nanocapsules are used to deliver creatine, then penetration improves, but the formulation complexity increases
Solution Approach 1:
The patent optimizes specific parameters of the nanocapsule formulation, including particle size (50-200 nm), lipid composition ratios, and creatine fatty ester concentration. By carefully controlling these parameters, the formulation achieves effective blood-brain barrier penetration while maintaining a relatively simple and scalable preparation process
4Speed
If nasal administration is used, then direct brain delivery is achieved, but the delivery system must be highly stable in plasma
Solution Approach 1:
The patent uses lipid nanocapsules with flexible lipid bilayer shells to protect creatine fatty esters from plasma esterase degradation. The lipid membrane acts as a protective barrier that maintains formulation stability in plasma while allowing rapid nasal delivery to the brain through the olfactory pathway
Solution Approach 2:
The lipid nanocapsule serves as an intermediary that protects the creatine fatty ester from enzymatic degradation in plasma during the rapid transit from nasal cavity to brain. This protective intermediary maintains composition stability while enabling fast delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The delivery system significantly increases creatine content in brain regions, improving cognitive function in CTD patients and demonstrating potential for industrial-scale production.
Implementation Method 1
A micro-emulsion containing dodecyl creatine ester, a glyceride-based oil, an omega-3 fatty ester, at least one non ionic surfactant and water
Implementation Method 2
at least one non ionic surfactant selected from the group consisting of polyoxylglycerides; polyethoxylated oils; polyethoxylated alcohols; propylene glycol esters of fatty acids; polyethylene glycol esters of fatty acids; alkyl polyglucosides; N-alkyl glucamine derivatives and amine oxides
Data Source
AI summary
A composition in the form of a micro-emulsion composed of an oil phase comprising at least one omega 3 fatty acid or salt thereof and at least one glyceride, an aqueous phase and one or more non ionic surfactant(s), said composition containing at least one creatine fatty ester or salt thereof. Further, a method for preparing such a composition and its use in medicine in particular for treating the brain creatine transporter deficiency disease.